drugset / Trial / NCT01691794
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse transcriptase inhibitor backbone therapy as part of their antiretroviral regimen.
Timeline
- Start
- 2012-11-30
- Primary completion
- 2014-10-31
- Completion
- 2017-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atazanavir | Other / unclassified | 150 mg | — |
| Comparator | Atazanavir | Other / unclassified | 200 mg | — |
| Comparator | Atazanavir | Other / unclassified | 300 mg | — |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |
Indications
No indication recorded.